Zafirlukast
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318990

CAS#: 107753-78-6

Description: Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), taken once daily. Zileuton (Zyflo), also used in the treatment of asthma via its inhibition of 5-lipoxygenase, is taken four times per day. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.


Price and Availability

Size
Price

25mg
USD 350
Size
Price

50mg
USD 550
Size
Price

100mg
USD 950

Zafirlukast, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 318990
Name: Zafirlukast
CAS#: 107753-78-6
Chemical Formula: C31H33N3O6S
Exact Mass: 575.20901
Molecular Weight: 575.68
Elemental Analysis: C, 64.68; H, 5.78; N, 7.30; O, 16.67; S, 5.57


Synonym: ICI-204219; ICI204219; ICI 204219; ICI-204,219; ICI 204,219; ICI204,219; Zafirlukast; brand names Accolate, Accoleit, and Vanticon.

IUPAC/Chemical Name: Cyclopentyl 3-{2-methoxy-4-[(o-tolylsulfonyl)carbamoyl]benzyl}-1-methyl-1H-indol-5-ylcarbamate

InChi Key: YEEZWCHGZNKEEK-UHFFFAOYSA-N

InChi Code: InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)

SMILES Code: O=C(OC1CCCC1)NC2=CC3=C(N(C)C=C3CC4=CC=C(C(NS(=O)(C5=CC=CC=C5C)=O)=O)C=C4OC)C=C2


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Chen CF, Lv Y, Zhang HP, Wang G. Does zafirlukast reduce future risk of asthma exacerbations in adults? Systematic review and meta-analysis. Multidiscip Respir Med. 2014 May 28;9(1):30. doi: 10.1186/2049-6958-9-30. eCollection 2014. Review. PubMed PMID: 24936302; PubMed Central PMCID: PMC4059702.

2: Murata Y, Sugimoto O. [Zafirlukast (Accolate): a review of its pharmacological and clinical profile]. Nihon Yakurigaku Zasshi. 2002 Apr;119(4):247-58. Review. Japanese. PubMed PMID: 11979731.

3: Dekhuijzen PN, Koopmans PP. Pharmacokinetic profile of zafirlukast. Clin Pharmacokinet. 2002;41(2):105-14. Review. PubMed PMID: 11888331.

4: Dunn CJ, Goa KL. Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma. Drugs. 2001;61(2):285-315. Review. PubMed PMID: 11270943.

5: Montelukast and zafirlukast in asthma. Drug Ther Bull. 1998 Sep;36(9):65-8. Review. PubMed PMID: 10194869.

6: Calhoun WJ. Summary of clinical trials with zafirlukast. Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 2):S238-45; discussion S245-8. Review. PubMed PMID: 9647606.

7: Holloway J, Ferriss J, Groff J, Craig TJ, Klinek M. Churg-Strauss syndrome associated with zafirlukast. J Am Osteopath Assoc. 1998 May;98(5):275-8. Review. Erratum in: J Am Osteopath Assoc 1998 Dec;98(12):676. Klinik M [corrected to Klinek M]. PubMed PMID: 9615559.

8: Adkins JC, Brogden RN. Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma. Drugs. 1998 Jan;55(1):121-44. Review. PubMed PMID: 9463793.

9: Hendeles L, Marshik PL. Zafirlukast for chronic asthma: convenient and generally safe, but is it effective? Ann Pharmacother. 1997 Sep;31(9):1084-6. Review. PubMed PMID: 9296252.

10: Kelloway JS. Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma. Ann Pharmacother. 1997 Sep;31(9):1012-21. Review. PubMed PMID: 9296243.

11: Spector SL. Management of asthma with zafirlukast. Clinical experience and tolerability profile. Drugs. 1996;52 Suppl 6:36-46. Review. PubMed PMID: 8941502.